Eptifibatide Injection now available

Bridgewater, New Jersey (USA), January 31, 2017 – Amneal Biosciences has launched its third generic medication for the healthcare institutional market.

Eptifibatide Injection, an AP-rated generic equivalent to Integrilin®, is available in 20 mg (2mg/mL) and 75 mg (0.75 mg/mL) strengths, sold in 10mL and 100mL vials. The product began shipping December 28, 2016 through wholesalers, distributors and directly to the trade.

“We’re very pleased to add eptifibatide to our growing portfolio of high-quality, affordable injectable medicines,” said Charles Lucarelli, Amneal Biosciences president. “Our primary focus remains providing reliable supply to hospitals, clinics and other health facilities as these are often the first line of care for patients.”

Amneal Biosciences (www.amnealbiosciences.com), a wholly-owned subsidiary of Amneal Pharmaceuticals LLC, is dedicated to the commercialization of high-barrier-to-entry generic injectables and specialty pharmaceuticals such as oncologics, anti-infectives and supportive care for healthcare providers and patients of all ages. The company’s expertise and focus on the unique needs and logistics of this market ensure the same level of quality and service for healthcare institutions and professionals that Amneal delivers to its retail customers.

About Amneal

Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of largest and fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal has now more than 4,000 employees in its operations in North America, Asia, Australia and Europe, working together to bring high quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas.

All trademarks listed in this release are property of their respective owners.